Optimal eCOA For Vaccine Trials

The precision evaluation of reactogenicity and immunogenicity is imperative in vaccine trials.

In this webinar, Dr. Stephan Bart, Executive Advisor of Infectious Disease and Vaccines, scrutinizes contemporary methodologies employed in vaccine trials, shedding light on the pivotal role that technologies like electronic Patient-Reported Outcomes (ePRO) play in both generating substantiating evidence and streamlining trial operations.

Access the full presentation below to learn more about the advantages of eCOA in vaccine trials.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader